

Press Release

Lonza to Hold Free Webinar on LIMS and MODA-EM™ Solution – A Comprehensive Solution for Pharmaceutical Manufacturing Quality Control

Cologne (DE) / Walkersville, MD (USA), 18 October 2016 – Lonza will hold a free 60-minute webinar on 2 November 2016 titled “LIMS and MODA-EM™ Solution – A Comprehensive Solution for Pharmaceutical Manufacturing Quality Control.”

During the webinar LIMS Administrators and QC professionals will learn how full integration of **LabVantage LIMS** and the **MODA-EM™ Solution** provides significant benefits to pharmaceutical quality-control organizations.

The following topics will be discussed:

- Why these two solutions have teamed up to seamlessly exchange data between their analytical and QC Micro platforms
- How this bi-directional interface provides unparalleled functionality and capabilities to increase operational efficiency, improve quality, and reduce cost
- Why an integrated approach enables customers to maximize the benefits of both solutions

Interested parties can register to attend the free webinar by selecting the link associated with their preferred time slot below:

- Session 1: Wednesday, 2 November 2016 – 9 AM EDT (New York) / 1 PM GMT (London) / 2PM CET (Berlin)
<https://attendee.gotowebinar.com/register/7843455634042258179>
Speaker: Robert Voelkner, LabVantage Solutions
Moderator: Richard Kelley, Lonza Bioscience Solutions
- Session 2: Wednesday, 2 November 2016 – 10 AM PDT (Los Angeles) / 1 PM EDT (New York)
<https://attendee.gotowebinar.com/register/204777820464047619>

Speaker: Robert Voelkner, LabVantage Solutions
Moderator: Richard Kelley, Lonza Bioscience Solutions

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
www.lonza.com

Press Release

Each webinar includes a Q&A session, and all registered participants will receive a PDF copy of the presentation with access to the recorded webinar shortly after the webinar takes place.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Cologne GmbH	Lonza Group Ltd	Lonza Group Ltd
Manager Marketing	Head Corporate	Head External
Communications	Communications	Communications
Petra Haberkamm	Dominik Werner	Constance Ward
Tel +49 221 991990	Tel +41 61 316 8798	Tel +41 61 316 8840
Fax +49 221 99199498	Fax +41 61 316 9540	Fax +41 61 316 9840
marcom.lbs@lonza.com	dominik.werner@lonza.com	constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.